The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...

Reverse-phase protein microarray was used to evaluate protein levels and activation/phosphorylation status of HER family (EGFR, HER2 and HER3) and downstream signaling molecules. The analysis was ...

The translational research program in the Schiff-Osborne lab, in close collaboration with clinicians, pathologists, bioinformaticians, and other leading experts in breast cancer, is primarily focused ...

The US Food and Drug Administration (FDA) has approved a label expansion for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, into biliary tract cancer (BTC).

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status ...

Basel, 31 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit ...

It binds to the HER3 receptor on cancer cells, and together with the HER2 receptor, activates signaling pathways that ensure the growth and survival of the cells. Even if this fuel runs out or the ...